Putting Science to Work

Archives / 2019

  • Syngene International Q2 profit up 64 pc to Rs 128 cr.

    Business Standard- 22/10/2019. Continued growth in our Discovery Services business, combined with consistent performances in our dedicated R and D centres and Development Services business were key to this performance.


  • Syngene announces Q1 FY20 results

    Express Pharma- 25/07/2019. Revenue up four per cent to Rs 441 crores, Profit After Tax increases nine per cent to Rs 72 crores. Further, Dr Mahesh Bhalgat appointed Chief Operating Officer (COO), confirms opening of new Hyderabad Research Centre.


  • Syngene Appoints Dr. Mahesh Bhalgat as COO

    The Pharma Times- 1/07/2019. Dr. Bhalgat is recognised for his contribution to the commercialization of diagnostic kits, biopharmaceuticals and WHO pre-qualification of vaccines. He has rich experience in diverse areas of biotechnology such as biotherapeutics, vaccines, ag-biotech, and research reagents.


  • Strategic Partnerships: The CRO game changer

    Chronicle Pharmabiz Newspaper- 13/06/2019. Today CROs want to move the value chain and are migrating to a more strategic relationship with their clients rather than exclusively compete on the cost arbitrage model. The market has evolved from the regular buyer-supplier relationship into one based on expanded strategic partnerships.


  • Syngene ranked as one of the fastest growing companies in India 2019

    Outlook Business- 24/05/2019. We are happy to share that Syngene was ranked as one of the 25 fastest growing companies in India by Outlook Business, a leading India based business publication, in a recent report. The ranking was based on sales CAGR for the past 5 years. As our CEO Jonathan Hunt puts it, ‘at the heart of Syngene’s success is the quality of service we have been able to provide our clients’.See below for the full report which includes an overview of our strategic approach, interaction with Syngene CEO Jonathan Hunt and perspectives of leading analysts.


  • Syngene International net surges by 18.5% in Q4 to Rs. 100 crore, bonus shares in ratio of 1:1

    Pharmabiz- 30/04/2019. During the quarter, Syngene and the Government of India's Biotechnology Industry Research Assistance Council (BIRAC) collaborated to set up a Centre for Advanced Protein Studies (CAPS) at its Bengaluru campus.


  • Syngene International wins CMO Leadership Award 2019

    BioSpectrum- 22/03/2019. Syngene was successfully rated across the six categories - Capabilities, Compatibility, Expertise, Quality, Reliability and Service – that were used to gauge the eventual winner.


  • Syngene Q3 net profit up 6 pc to Rs 87 cr

    Business Standard- 22/01/2019. Consolidated total revenue of the company stood at Rs 484.4 crore for the quarter under consideration as against Rs 399.3 crore for the same period a year ago.


Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget